Skip to main content
. Author manuscript; available in PMC: 2016 Nov 17.
Published in final edited form as: Immunity. 2015 Nov 17;43(5):959–973. doi: 10.1016/j.immuni.2015.10.014

Figure 2. Glycan specificity of V2 apex bnAbs (See also Tables S2-S3).

Figure 2

A. V2 apex bnAb neutralization of Env variants displaying differing glycan composition in the context of the 16055.2.3 isolate. Two Abs from each V2 apex bnAb prototype were tested for neutralization against 16055.2.3 wild type (WT), N156K, N160K glycan variants, and viruses produced in the presence of glycosidase inhibitors kifunensine (Kif) and swainsonine (Swain). B. The four V2 apex bnAb prototypes were tested in ELISA binding to Gallanthus Nivalis Lectin (GNL)-purified BG505.Env.C2.SOSIP.664 soluble trimer glycovariants. The gp120-gp41 glycan dependent Ab PGT151, the CD4bs Ab VRC01 and a Dengue Ab (DEN3) were used as controls.

C. Reactivity of V2 apex bnAbs with glycans on a glycan microarray. The V2 apex bnAbs were tested for reactivity on a glycan array. The data are shown as Relative Fluorescence Units (RFU) and the error bars represent the average percentage error for all data points reported. The symbol for each monosaccharide is indicated. The glycan dependent antibody PGT151 was used as control.